Medicenna Therapeutics announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer, CMO, to lead the development strategy and execution of Medicenna’s clinical programs. Dr. Gardner’s career in the biopharmaceutical industry spans over two decades. Most recently, Dr. Gardner served as CMO at Harbour BioMed advancing novel antibody and bispecific therapeutics in oncology.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDNA:
- Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
- Medicenna Therapeutics presents preclinical MDNA223 BiSKIT data
- Medicenna Announces Results of Annual and Special Meeting of Shareholders
- Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy
- Medicenna Therapeutics appoints Jeff Caravella as CFO